MedTrace Logo

A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer

NCT02828124 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2019-01-30

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety and tolerability of BMS-986183 in patients with liver cancer.

Conditions

Interventions

BIOLOGICAL

BMS-986183

specified dose on specified days

BIOLOGICAL

Nivolumab

specified dose on specified days

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-23
Primary Completion
2018-01-08
Completion
2018-01-08
FDA Drug
Yes

Countries

  • Canada
  • Singapore
  • South Korea
  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02828124 on ClinicalTrials.gov